Immunotherapy for non-small cell lung cancer treatment
https://doi.org/10.18027/2224-5057-2016-3-17-24
Abstract
Non–small cell lung cancer (NSCLC) is the leading cause of cancer related mortality worldwide. Many patients present with metastatic disease and traditional CT treatment fails to provide long- term benefit for most patients. Patients with driver mutations demonstrate substantially better response rate and progressionfree survival when the appropriate targeted agents are used, but only approximately 25%-30% of patients with NSCLC have actionable mutations. Novel treatment options are clearly needed for patients with lung cancer. Immuno-oncology recently has been identified as effective second line therapy of NCSLC. Almost all of this progress has been due to the development of PD‑1 and PD-L1 inhibitors. In this review, we explore the data currently available for these agents.
About the Authors
K. K. LAKTIONOV
FGBU (Federal State Budgetary Institution) N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, PhD, DSc, chief of department
K. A. SARANTSEVA
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Belarus
Belarus
post-graduate student
V. V. BREDER
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
MD, PhD, leading research scientist
M. A. OKRUZHNOVA
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
associate scientist
Russian Federation
associate scientist
M. V. PEREGUDOVA
FGBU N. N. Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Russian Federation
associate scientist
Russian Federation
associate scientist
References
1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5– 9.
2. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer. 2015; 136(5): 359– 86.
3. Kaprin A.D., Starinskij V.V., Petrova G.V. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2014 g. M. –2015.
4. Davydov M.I., Polockij B.E. «Sovremennye principy vybora lechebnoj taktiki i vozmozhnosti hirurgicheskogo lecheniya nemelkokletochnogo raka legkogo», sbornik Novoe v terapii raka legkogo. M. – 2003.
5. Cheng D. et al. Video-Assisted Thoracic Surgery in Lung Cancer Resection: A Meta- analysis and Systematic Review of Controlled Trials. Innovations (Philadelphia). 2007; 2(6): 261–292.
6. Detterbeck F.C., Postmus P.E., Tanoue L.T. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5): 191–210.
7. Tanoue L.T., Detterbeck F.C. New TNM classification for nonsmall- cell lung cancer. Expert review of anticancer therapy. 2009; 9(4): 413–423.
8. Pishchik V.G. et al. Pervyj opyt vypolneniya torakoskopicheskih lobehktomij s bronhoplastikoj. Vestnik hirurgii imeni I. I. Grekova. 2015; 174 (1): 59–65.
9. Downey R.G. et al. Video-Assisted Thoracic Surgery for Lung Cancer Resection: A Consensus Statement of the International Society of Minimally Invasive Cardiothoracic Surgery (ISMICS) 2007. Innovations (Philadelphia). 2007; 2(6); 293–302.
10. Tyulyandin S.A., Polockij B.E. Taktika lecheniya nemelkokletochnogo raka legkogo IIIC–IV stadii. Prakticheskaya onkologiya. 2006; 7 (3): 161–169.
11. Orlova R.V. Sovremennoe standartnoe lechenie bol’nyh nemelkokletochnym rakom legkogo s uchetom stadii zabolevaniya. Prakticheskaya onkologiya. 2000; 3: 17–20.
12. Ramnath N. et al. Treatment of Stage III Non-small Cell Lung Cancer. Diagnosis and Management of Lung Cancer, 3rd edition: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2013; 143 (5): 314–340.
13. Albain K.S., Rusch V.W., Crowley J.J., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995; 13(8): 1880–92.
14. Le Chevalier T., Arriagada R., Quoix E. et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non–small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417–423.
15. Marenich A.F., Gorbunova V.A., Rodnikova E.G., Fedenko A.A. Kolesnik A.A. «Raznoobrazie rezhimov kombinirovanoj himioterapii v lechenii nemelkokletochnogo raka legkogo». Trudnyj pacient, M. – 2007.
16. Bansal P., Osman D., Gan GN, Simon G.R., Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non- Squamous NSCLC. Front Oncol. 2016; 6: 112.
17. Asciertoa P.A., Marincolab F.M.. 2015: The year of anti-PD‑1/ PD-L1s against melanoma and beyond. EBioMedicine. 2015; 2 (2): 92–93.
18. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co- stimulates T-cell proliferation and interleukin‑10 secretion. Nat Med. 1999; 5(12): 1365– 1369.
19. Bickels J., Kollender Y., Merinsky O., Meller I. Coley’s toxin: historical perspective. The Israel Medical Association journal: IMAJ. 2002; 4: 471–2.
20. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012; 23 (8): 6–9.
21. Ascierto P. A. et al. What have we learned from cancer immunotherapy in the last 3 years? Journal of Translational Medicine. 2014, 12: 141.
22. Hiraoka K., Miyamoto M., Cho Y. et al. Concurrent infiltration by CD8+ T cells and CD4+ Tcells is a favourable prognostic factor in non-small cell lung carcinoma. Br J Cancer. 2006; 94(2): 275–80.
23. Al-Shibli K.I., Donnem T., Al-saad S et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer Clin. Cancer Res. 2008; 14: 5220–5227.
24. Kawai O., Ishii G., Kubota K. et al. Predominant infiltration of macrophages and CD8+ T cells in cancer nests is a significantpredictor of survival in stage IV non-small cell lung cancer. Cancer. 2008; 113: 1387–1395.
25. Petersen R.P., Campa M.J., Sperlazza J. et al. Tumor infiltrating Foxp3+ regulatory T cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107: 2866–2872.
26. Shimizu K., Nakata M., Hirami Y. et al. Tumor infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase‑2 expression and are associated with recurrence in resrcted non-small cell lung cancer. J. Thorac. Oncol. 2010; 5: 585–590.
27. Mayor M., Yang N., Sterman D., Jones D.R., Adusumilli PS. Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg. 2016; 49(5):1324–33.
28. Pennell N.A. Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Semin Oncol. 2015; 42 (2): 3–10.
29. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD‑1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11 (11): 3887–95.
30. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med. 2002; 8: 793–800.
31. Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004; 4(5): 336–347.
32. Okazaki T., Honjo T. PD‑1 and PD‑1 ligands: from discovery to clinical application. Int Immunol. 2007; 19:813–2.
33. Riley J.L. PD‑1 signaling in primary T cells. Immunol Rev. 2009;229:114–25.
34. Sznol M., Chen L. Antagonist antibodies to PD‑1 and B7- H1 (PD-L1) in the treatment of advanced human cancer response. Clin Cancer Res. 2013; 19: 5542.
35. Ota K., Azuma K., Kawahara A., et al. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.Clin Cancer Res. 2015; 21: 4014–21.
36. Pan Z.K., Ye F., Wu X., et al. Clinicopathological and prognostic significance of rogrammed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.J Thorac Dis. 2015; 7: 462–70.
37. Gettinger S.N., Horn L., Gandhi L., et al. Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS‑936558, ONO‑4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18): 2004– 12.
38. Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21): 2018–28.
39. Brahmer J., Reckamp K.L., Baas P., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123–35.
40. Borghaei H., Paz-Ares L., Horn L., et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–39.
41. Herbst R.S., Baas P., Kim D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE‑010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540–50.
42. Fehrenbacher L., Spira A., Ballinger M. et al. Atezolizumab versus docetaxel for patients with previously treated nonsmall- cell lung cancer (POPLAR): a multicenter, openlabel, phase 2 randomized controlled trial. Lancet. 2016; 387(10030): 1837–46.
43. Chae Y.K., Pan A., Davis A.A., et al. Biomarkers for PD‑1/PDL1 Blockade Therapy in Non- Small-cell Lung Cancer: Is PD-L1 Expression a GoodMarker for Patient Selection? Clin Lung Cancer. 2016: S1525–7304 (16): 30057–2.
Review
For citations:
LAKTIONOV K.K., SARANTSEVA K.A., BREDER V.V., OKRUZHNOVA M.A., PEREGUDOVA M.V. Immunotherapy for non-small cell lung cancer treatment. Malignant tumours. 2016;(3):17-24. (In Russ.) https://doi.org/10.18027/2224-5057-2016-3-17-24
Views:
1371
Email this article 